Nanogen signs licensing agreement with Quest Diagnostics

Under the licensing agreement, Quest Diagnostics will have rights to use and sell products and services incorporating the MGB Probe technology. Terms of the end user licensing agreement include an upfront fee and royalties paid on tests sold using the licensed technology.

Merl Hoekstra, vice president of corporate and business development at Nanogen, said: “We’re proud that Quest Diagnostics, the world’s leader in diagnostic testing, is using our minor groove binder (MGB) technology and incorporating it into some of their laboratory developed molecular tests. We’re proud of the growing reputation and the expanding base of licensed end users of our technology.”